CSF1R and neoplasm: Treatment with PLX-3397, an inhibitor of CSF-1R which is required for MDSC maturation and tumour localisation, was demonstrated to inhibit the accumulation of MDSCs following BNCT, and an ~3.5-fold increase in tumour infiltrating CD8+ T cells was noted compared to BNCT alone, enhancing the immune response to the tumour.